Ovid Therapeutics is sponsoring a clinical research study called the STARS study. The STARS study will evaluate the safety and effectiveness of an investigational medicine on various aspects associated with Angelman syndrome.
The STARS study will enroll approximately 75 people in a Phase 2 double-blind placebo-controlled randomized study.
More information can be found at www.angelmanstudy.com.
Criteria and Expectations
- Participant must be at least 13 years old and have a confirmed diagnosis of Angelman syndrome
- The primary caregiver for the individual with Angelman syndrome will need to be able to complete study activities and answer some questions from the study doctor at prescheduled times.
- The study will last approximately four months and include phone appointments and four in-person visits to the medical center or study site conducting the study.
The Angelman Syndrome Foundation does not endorse any clinical trial or study, but provides information to the AS community for its own consideration.